Scopia Surgical
Scopia Surgical (also referred to as Scopia Tech) is a Montreal, Canada-based surgical navigation company founded in 2024 by CEO Gabriel Rivest and CTO Sébastien Delorme.
Position in SVTR
Snapshot 2026-10-26- Startup SignalsRankedof 2,343new
- Life SciencesRankedof 248
- Medtech DeviceRankedof 41
- Medical ImagingRankedof 16
About
Scopia Surgical (also referred to as Scopia Tech) is a Montreal, Canada-based surgical navigation company founded in 2024 by CEO Gabriel Rivest and CTO Sébastien Delorme. It builds an AI surgical navigation software platform that fuses real-time spatial intelligence with patient-specific digital twins generated from CT/MRI scans — positioned as "a GPS for minimally invasive robotic surgery" — for gynaecologic, urologic and colorectal procedures, integrating into existing surgical workflows without additional tracking hardware. The roughly seven-person team is backed by Quebec innovation bodies including MAIN, Centech ETS and Medteq+.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 1
Investor· 4
Founders / team· 2
Funding history
- 2026-09-01Pre-SeedC$2.65 million
Investors · Linearis Ventures, Anges Québec, Fonds Impulsion, HaloHealthSource · pulse2.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Scopia Surgical
AI surgical navigation software combining real-time spatial intelligence and patient-specific digital twins for robot-assisted and minimally invasive soft-tissue surgery
Pre-Seed · $3M · 2026-09
$3M
United States
BusinessLatest roundTotal raisedDate- Dopl Technologies
Hardware-agnostic teleoperated robotic ultrasound system
Seed · $8M · 2026-07
$8M - Voio
Unified AI image reading and reporting platform (Pillar-0 model) to support radiology diagnosis across all modalities
Seed · $9M · 2025-11
$9M - Aurenar
V-Link, a non-invasive, single-use neuromodulation platform that uses low-energy transcutaneous auricular vagus nerve stimulation via the outer ear to modulate inflammation and reduce fatal complications in ICU patients; first indication is cerebral vasospasm after aneurysmal subarachnoid hemorrhage; FDA Breakthrough Device designation
Seed · $6M · 2026-07
$6M
China
BusinessLatest roundTotal raisedDate- 睿心医疗
Developer of AI precision diagnosis and treatment platforms for cardiovascular and cerebrovascular disease and of vascular interventional surgical robots.
Strategic · 2026-07
— - 智愈医疗
metaFlow high-energy waterjet surgical robot for ultrasound-guided resection of enlarged prostate tissue
Series A · $8M · 2024-05
$8M - Krinwave
Super-resolution ultrasound imaging systems (kOS ultrasound operating system + HUS hardware platform), focused on transcranial brain ultrasound and clinical/research ultrasound diagnostics
Undisclosed · 2026-10
—
Europe
BusinessLatest roundTotal raisedDate- Nami Surgical
Miniature ultrasonic medical devices for surgery; high-performance small ultrasonic scalpels designed to overcome obstacles in robot-assisted surgery
Undisclosed · $4M · 2024-05
$4M - Soundsafe Care
Robotic focused ultrasound devices for noninvasive tumor ablation, launching first with veterinary certification, then expanding to human tumor treatment.
$2M
$2M - XRlabs
XRlabs SIM (CT/MRI to 3D digital twins for surgical rehearsal) and SurgicalOS (real-time AI video and instrument tracking) for hospitals and surgeons
Seed · 2026-10
—
Other / unspecified
BusinessLatest roundTotal raisedDate- CustoMED
AI and 3D printing to produce patient-specific orthopedic surgical tools and implants
Seed · $6M · 2025-11
$6M - Nuclivision
AI software that enhances PET scans for faster, lower-radiation imaging while maintaining diagnostic accuracy
Undisclosed · $6M · 2025-04
$6M - UltraSight
AI-guided cardiac ultrasound workflow platform (Echosystem) enabling non-specialist clinicians to perform diagnostic-grade echocardiograms at the bedside
Series B · $42M · 2026-09
$42M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 19 at a nearby stage · 1 in North America
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 11 at a nearby stage · 1 in North America
Request intro →8VC
14 Life Sciences deals in the last 24 months · 6 at a nearby stage · 1 in North America
Request intro →GV
14 Life Sciences deals in the last 24 months · 3 at a nearby stage · 1 in North America
Request intro →Founders Fund
10 Life Sciences deals in the last 24 months · 3 at a nearby stage · 1 in North America
Request intro →OrbiMed Advisors
9 Life Sciences deals in the last 24 months · 3 at a nearby stage · 2 in North America
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.